is this new technology the end for fermiscan, page-19

Agreed. No need to shout. But the claims that affect the SP don't always come from the company....
See my earlier post that a major confounder is the way the information is interpreted and extrapolated by a nonmedical market. Anything malignancy related is far more emotive than, say, anything to do with lupus. Consequently much more open to [market] action based upon misunderstanding.